Abstract
Aqueous extracts of Emblica officinalis and Chyavanaprash, an indigenous drug preparation in which Emblica officinalis is a major ingredient, were found to inhibit 20-methylcholanthrene-induced sarcoma and to increase the life span of the animals. Oral administration of Emblica (10 mg/mice) and Chyavanaprash (50 mg/mice) extracts produced a 75% reduction in the development of sarcoma. The aqueous extract of Emblica was also found to inhibit the activation and mutagenicity of 2-acetamidofluorene (2-AAF) as well as that of direct-acting mutagens N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and 4-nitro-O-phenylenediamine (4-NPDA). The extract was found to inhibit microsomal P-450 enzyme, aniline hydroxylase. The activity of the extract may be mainly related to its oxygen radical-scavenging activity as well as to inhibition of Phase-I enzymes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
